SCHEMBL6417121

SCHEMBL6417121

CCCc1cc(O)c(C)cc1OCCN(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.52
KDM4E B2RXH2 4/20 0.42
CHRNA4 P43681 2/20 0.41
ADRA1D P25100 2/20 0.41
ADRA1A P35348 2/20 0.41
ADRA1B P35368 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
ADRA2A P08913 1/20 0.41
PKM P14618 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
HTR2C P28335 1/20 0.41
HRH1 P35367 1/20 0.41
DRD3 P35462 1/20 0.41
OPRK1 P41145 1/20 0.41
HIF1A Q16665 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
BLM P54132 1/20 0.40
HMGCR P04035 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696879 0.80 CYP1A2 (0.64) ESR1KDM4ECHRNA4ADRA1DADRA1A
SCHEMBL5207072 0.75 ADRA1D (0.65) ESR1KDM4ECHRNA4ADRA1DADRA1A
SCHEMBL25329688 0.74 ESR1 (0.40) ESR1KDM4ESMN1; SMN2ALDH1A1LMNA
Hydrochloric Acid SCHEMBL29711062 0.73 SMN1; SMN2 (0.66) ESR1KDM4ECHRNA4ADRA1DADRA1A
SCHEMBL6416957 0.73 CYP1A2 (0.47) ESR1KDM4ECHRNA4ADRA1DADRA1A
SCHEMBL4696872 0.73 CYP1A2 (0.47) ESR1KDM4ECHRNA4ADRA1DADRA1A
SCHEMBL4695768 0.73 CYP1A2 (0.47) ESR1KDM4ECHRNA4ADRA1DADRA1A
SCHEMBL25328003 0.73 ESR1 (0.49) ESR1
SCHEMBL17147252 0.73 KDM4E (0.62) ESR1KDM4ECHRNA4ADRA1DADRA1A
SCHEMBL23387419 0.71 HMGCR (0.45) ESR1KDM4ECYP1A2CYP2D6PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds NITROMED, INC. (US) 2005-08-25 US disclosed
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use GARVEY DAVID S (US) 2002-10-03 US disclosed
EP-1018879-A4 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES NITROMED INC (US) 2002-07-24 EP disclosed
EP-1018879-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES Nitromed, Inc. (US) 2000-07-19 EP disclosed
WO-1997027749-A1 NITROSATED AND NITROSYLATED α-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES NITROMED, INC. (US) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187222-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds ADRB1, ADRB3, ADRA1D ESR1 491/4885KDM4E 2810/4885CHRNA4 38/4885
US-20020143007-A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use ADRB1, ADRB3, ADRA1D ESR1 686/4885KDM4E 2640/4885CHRNA4 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.